NCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
Clinical Trials
18 trialsNCT05104866 2026-02-04
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
Phase 3 Active not recruiting
NCT05374512 2026-01-27
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca
Phase 3 Active not recruiting
NCT03734029 2025-10-06
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo
Phase 3 Active not recruiting
NCT02061085 2025-06-08
MERIBEL
MedSIR
Phase 2 Completed
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05824975 2024-11-25
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
Phase 1/2 Recruiting
NCT06539559 2024-08-06
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT01795586 2022-10-31
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02824575 2022-04-04
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
Montefiore Medical Center
Phase 1 Terminated
NCT03795012 2021-08-31
Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients
MedSIR
Phase 2 Terminated
NCT02551263 2021-06-11
E-SPEC
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Completed
NCT01596751 2020-07-17
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
University of California, San Francisco
Phase 1/2 Completed
NCT01961544 2016-10-07
ESKIMO
Eisai Inc.
Phase 4 Completed
NCT02175446 2016-06-15
GIM11-BERGI
Consorzio Oncotech
Phase 2 Unknown
NCT00278993 2014-07-14
Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
Eisai Inc.
Phase 2 Completed
NCT00069264 2011-12-20
Study of E7389 in Patients With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed